{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"The MTD will be defined as the dose that is associated with a true DLT rate of 25%. The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached.","groups":[{"description":"Study participants will receive an infusion of 0.5 mg/kg of ideal body weight of DOTA-BC8 trace labeled with \\~5-10 mCi of Indium-111 to evaluate biodistribution and calculate the radiation absorbed doses to major organs and the whole body. The subsequent therapy infusion of Yttrium-90-DOTA-BC8 will deliver an amount of Yttrium-90 calculated not to exceed the target dose to the critical normal organ receiving the highest radiation dose. The therapy dose will be administered on approximately day -12 of the preparative regimen, which will typically be approximately 1 to 2 weeks after the biodistribution dose.","id":"OG000","title":"Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)"}],"paramType":"NUMBER","populationDescription":"Study participants who completed the study regimen.","reportingStatus":"POSTED","timeFrame":"Within the first 30 days following transplant","title":"The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk MDS.","type":"PRIMARY","unitOfMeasure":"Gy"}